New and emerging disease modifying therapies for multiple sclerosis

  title={New and emerging disease modifying therapies for multiple sclerosis},
  author={S. Saidha and C. Eckstein and P. Calabresi},
  journal={Annals of the New York Academy of Sciences},
  • S. Saidha, C. Eckstein, P. Calabresi
  • Published 2012
  • Medicine
  • Annals of the New York Academy of Sciences
  • Several disease‐modifying drugs (DMDs) are currently approved for the treatment of multiple sclerosis (MS). Recently, there has been increased identification and development of potential new treatments that may modulate the MS disease process, including oral therapies. Many of the newly approved MS therapies, as well as those in ongoing clinical trials, have the advantage of improved efficacy and/or being oral and more convenient, as compared to conventional injectable first‐line MS therapies… CONTINUE READING
    46 Citations

    Topics from this paper

    Established and novel disease‐modifying treatments in multiple sclerosis
    • 106
    Pegylated Interferons: A Nurses’ Review of a Novel Multiple Sclerosis Therapy
    • Anne Howley, M. Kremenchutzky
    • Medicine
    • The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
    • 2014
    • 5
    Influence of Peripheral inflammation on the progression of multiple sclerosis: Evidence from the clinic and experimental animal models
    • 27
    • Highly Influenced
    Role of Regulatory T Cells in Pathogenesis and Biological Therapy of Multiple Sclerosis
    • M. Buc
    • Medicine
    • Mediators of inflammation
    • 2013
    • 70
    • PDF
    Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis
    • 1


    Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
    • A. Tselis
    • Medicine
    • Current opinion in investigational drugs
    • 2010
    • 10
    Treatment of multiple sclerosis with anti-CD20 antibodies.
    • 109
    A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    • 2,065
    • PDF
    Oral fingolimod (FTY720) in multiple sclerosis
    • 198
    Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    • 1,798
    • PDF